APLS
NASDAQApellis Pharmaceuticals Inc.
Price$41.05+18.22 (+79.79%)
2026-02-092026-05-13
News · 26 weeks126-96%
2025-12-142026-06-07
Mix6490d
- Insider23(36%)
- SEC Filings23(36%)
- Other14(22%)
- Earnings2(3%)
- Analyst1(2%)
- Leadership1(2%)
Latest news
25 items- SECAmendment: SEC Form SCHEDULE 13G/A filed by Apellis Pharmaceuticals Inc.SCHEDULE 13G/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
- SECSEC Form 15-12G filed by Apellis Pharmaceuticals Inc.15-12G - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
- INSIDERDirector Dunlop A. Sinclair returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERVP/Chief Accounting Officer Chopas James George was granted 38,244 shares and returned 76,650 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding tax4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERDirector Dolsten Mikael returned 14,312 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief Research and Development Meltzer Leslie returned 174,854 shares to the company and was granted 67,830 shares, closing all direct ownership in the company (SEC Form 4) to cover withholding tax4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERDirector Fonteyne Paul R. returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) to cover taxes4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief Financial Officer Sullivan Timothy Eugene was granted 159,080 shares and returned 270,413 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax liability)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERDirector Machiels Alec returned 20,311 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding tax)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief Scientific Officer Deschatelets Pascal was granted 90,040 shares and returned 135,445 shares to the company, closing all direct ownership in the company (SEC Form 4) to satisfy withholding obligation4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERDirector Chan Gerald returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) (for withholding tax)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief Technical Officer Nicholson Nur was granted 133,364 shares and returned 221,303 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERDirector Walbert Keli returned 16,293 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief Business & Strat Officer Delong Mark Jeffrey was granted 115,165 shares and returned 186,543 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERDirector O'Brien Stephanie Monaghan returned 24,188 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief People Officer Boucher Kelley was granted 45,219 shares and returned 173,023 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERDirector Wheeler Craig A returned 23,071 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERGeneral Counsel Watson David O. was granted 153,737 shares and returned 267,033 shares to the company, closing all direct ownership in the company (SEC Form 4) (for tax liability)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief Executive Officer Francois Cedric was granted 524,786 shares and returned 875,644 shares to the company, closing all direct ownership in the company (SEC Form 4) (tax withholding)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- INSIDERChief Medical Officer Baumal Caroline was granted 67,646 shares and returned 118,953 shares to the company, closing all direct ownership in the company (SEC Form 4) (withholding obligation)4 - Apellis Pharmaceuticals, Inc. (0001492422) (Issuer)
- SECAmendment: SEC Form SCHEDULE 13D/A filed by Apellis Pharmaceuticals Inc.SCHEDULE 13D/A - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
- SECSEC Form 25-NSE filed by Apellis Pharmaceuticals Inc.25-NSE - Apellis Pharmaceuticals, Inc. (0001492422) (Subject)
- SECSEC Form S-8 POS filed by Apellis Pharmaceuticals Inc.S-8 POS - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
- SECSEC Form S-8 POS filed by Apellis Pharmaceuticals Inc.S-8 POS - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
- SECSEC Form S-8 POS filed by Apellis Pharmaceuticals Inc.S-8 POS - Apellis Pharmaceuticals, Inc. (0001492422) (Filer)
APLS FAQ
7 questionsWhat does Apellis Pharmaceuticals Inc. do?
Apellis Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. Its lead product candidate is pegcetacoplan that is in Phase III clinical trials for the treatment of geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria (PNH) diseases; cold agglutinin disease; C3 glomerulopathy; and other glomerular diseases, such as IgA nephropathy, primary membranous nephropathy, and lupus nephritis. The company also...Where does APLS stock trade?
Apellis Pharmaceuticals Inc. (APLS) is listed on NASDAQ.What sector and industry is APLS in?
Apellis Pharmaceuticals Inc. operates in the Health Care sector, Biotechnology: Pharmaceutical Preparations industry.When did Apellis Pharmaceuticals Inc. go public?
Apellis Pharmaceuticals Inc. (APLS) completed its IPO in 2017.What are analysts saying about APLS?
Apellis Pharmaceuticals Inc. has had 8 recent analyst actions on file. The most recent action was from Roth Capital: Buy with a $3100.00 price target on 2026-03-13. Recent price targets range from $1800.00 to $3200.00.What companies are similar to APLS?
Notable peers in the same industry include LLY (Eli Lilly and Company), AZN (AstraZeneca PLC), JNJ (Johnson & Johnson), ABBV (AbbVie Inc.), MRK (Merck & Company Inc.). Compare APLS side-by-side with any of them on Quantisnow.How can I track APLS on Quantisnow?
Quantisnow aggregates Apellis Pharmaceuticals Inc.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow APLS to receive live email and push alerts on every new disclosure.